Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.Â
Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.
Royal College of Surgeons in Ireland preclinical research found that venetoclax, a medication currently approved for leukemia, may have benefits for patients with multiple myeloma when used in combination with another drug—a demethylase inhibitor called 5-azacytidine. This discovery offers a new avenue of treatment options for the currently incurable disease.
Researchers from the University of Southern California found a genetic variant contributing to disparities in childhood leukemia risk. The variant, located on the IKZF1 gene, helps explain why Hispanic/Latino children face a higher risk of acute lymphoblastic leukemia and offers insights about what causes the disease.
The composition of the gut microbiomes in a group of rectal cancer patients reveals distinct signatures by race, ethnicity, and age of onset, with white Hispanics showing significant presence of one specific type of bacteria, UT Southwestern Medical Center researchers report.Â
Research evaluating data from the American College of Surgeons National Cancer Database (NCDB) showed a 15-20% decrease in newly diagnosed breast cancer cases reported to Commission on Cancer sites in 2020, compared to 2019.
A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body.
A study led by USC Norris Comprehensive Cancer Center, part of the Keck School of Medicine of USC, analyzed data on red and processed meat intake from 29,842 people with colorectal cancer and 39,635 people without cancer.Â
In a paper published in The Lancet Public Health, researchers sound a clarion call for greater investment, at both the community and institutional level, in establishing support for grief-related suffering.
